No Data
Xiangxue Pharmaceutical (300147.SZ): TAEST16001 injection is currently in Phase II clinical stage.
Gelonghui November 6th | xiangxue pharmaceutical (300147.SZ) stated on the investor interaction platform that the TAEST16001 injection is currently in Phase II clinical stage, and the progress of research and development will be disclosed to the public in the form of announcements based on clinical conditions and information disclosure rules.
Express News | Institutions net buy 10 shares on the Dragon Tiger List, xiangxue pharmaceutical ranks first.
Top gainer list: Xiangxue Pharmaceutical rose by 20% today, with four institutions net buying 0.101 billion yuan.
格隆汇 October 29th | Xiangxue Pharmaceutical (300147.SZ) hit the daily 20% limit up, with a turnover of 2.714 billion yuan and a turnover ratio of 31.52%. According to the Dragon and Tiger List data, the speculative investors known as 'leisurely investors' are among the top sellers, with a net sell of 89.573 million yuan; four institutions bought 0.287 billion yuan and sold 0.186 billion yuan, resulting in a net purchase of 0.101 billion yuan. (GeLongHui)
Express News | Xiangxue Pharmaceutical and others have resumed execution of 0.15 billion.
Xiangxue Pharmaceuticals: Report for the third quarter of 2024
Xiangxue Pharmaceutical (300147.SZ): a net loss of 0.218 billion yuan in the first three quarters.
GeLongHui October 25th | Xiangxue Pharmaceutical (300147.SZ) released the third quarter report for 2024, with the company achieving a revenue of 1.534 billion yuan in the first three quarters, a decrease of 11.26% year-on-year; net income attributable to shareholders of the listed company was -0.218 billion yuan; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was -0.205 billion yuan; basic earnings per share -0.3300 yuan.
No Data
No Data